Top Markets
#1 The Black Bull The Black Bull +22.59%
#2 EXOD EXOD +22.08%
#3 SSV Network SSV Network +21.25%
#4 XPIN Network XPIN Network +21.09%
#5 Useless Coin Useless Coin +20.60%
#6 Ore Ore +20.14%
#7 GALA GALA +19.48%
#8 Wrapped XPL Wrapped XPL +18.69%
#9 Plasma Plasma +18.68%
#10 Unit Plasma Unit Plasma +18.68%
Coin of the day
The Black Bull The Black Bull
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Sirnaomics Ltd. Sirnaomics Ltd.

Sirnaomics Ltd.

2257
Rang in Aktien #25047
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in... Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant medical needs across the United States and the People's Republic of China. Its leading pipeline assets include STP705, which is being investigated for conditions such as cutaneous squamous cell carcinoma in situ, basal cell carcinoma, various liver-related cancers (cholangiocarcinoma, hepatocellular carcinoma, liver metastases), as well as for keloid scar remodeling, hypertrophic scarring, and fat sculpting. Another prominent candidate, STP707, is designed to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, and both liver and lung fibrosis. Beyond these lead programs, Sirnaomics is advancing STP355 for a range of cancers; STP369 for head and neck/bladder cancers; STP779 for liver, lung, and pancreatic cancers; and STP902 for breast cancer. The company's portfolio also extends to infectious diseases with STP702 for influenza, STP908 for COVID-19, the RIM730 COVID-19 vaccine, and STP909 for HPV/cervical cancer. Furthermore, its developmental pipeline encompasses STP122G for thrombotic disorders, STP125G for hypertriglyceridemia, STP144G for complement-mediated ailments, STP133G for cardiometabolic conditions, and STP155G for hepatitis B virus.
Aktienkurs
$0.49443488
Marktkapitalisierung
$53.84M
Veränderung (1 Tag)
-0.90%
Veränderung (1 Jahr)
-60.89%
Land
US
Handel Sirnaomics Ltd. (2257)

Kategorie

Healthcare
EPS für Sirnaomics Ltd. (2257)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Sirnaomics Ltd. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Sirnaomics Ltd. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $2.98 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US